2. Szuba A, Cooke JP. Thromboangiitis obliterans. An update on Buerger’s disease. West J Med 1998;168:255-60.
3. Ciricillo SF, Weinstein PR. Lumbar spinal stenosis. West J Med 1993;158:171-7.
6. Amundsen T, Weber H, Nordal HJ, et al. Lumbar spinal stenosis: conservative or surgical management?: a prospective 10-year study. Spine (Phila Pa 1976) 2000;25:1424-35. discussion 35-6.
7. Ammendolia C, Stuber KJ, Rok E, et al. Nonoperative treatment for lumbar spinal stenosis with neurogenic claudication. Cochrane Database Syst Rev 2013;(8):CD010712.
8. Takahashi J, Kobayashi H, Wakabayashi S, et al. The effect of a prostaglandin E-1 derivative on the symptoms and quality of life of patients with lumbar spinal stenosis. J Orthop Sci 2013;18:208-15.
9. Do KH, Kim TH, Chang MC. Effects of interlaminar epidural steroid injection in patients with moderate to severe lumbar central spinal stenosis: a prospective study. Ann Palliat Med 2020;9:163-8.
10. Yaksi A, Ozgönenel L, Ozgönenel B. The efficiency of gabapentin therapy in patients with lumbar spinal stenosis. Spine (Phila Pa 1976) 2007;32:939-42.
11. Kim HJ, Kim JH, Park YS, et al. Comparative study of the efficacy of limaprost and pregabalin as single agents and in combination for the treatment of lumbar spinal stenosis: a prospective, double-blind, randomized controlled non-inferiority trial. Spine J 2016;16:756-63.
12. Matsudaira K, Seichi A, Kunogi J, et al. The efficacy of prostaglandin E1 derivative in patients with lumbar spinal stenosis. Spine (Phila Pa 1976) 2009;34:115-20.
17. Beyth RJ, Landefeld CS. Anticoagulants in older patients. A safety perspective. Drugs Aging 1995;6:45-54.
18. Uratsuji M, Iguchi T, Kataoka O, et al. The optimal dose for OP-1206 ∙ α-CD on lumbar spinal canal stenosis: multi-center comparative double-blind clinical study. Rinsho Iyaku 1996;12:489-509. (Japanese).
20. Sugiyama N, Sasayama D, Amano N. Massive epistaxis and subconjunctival hemorrhage due to combination of paroxetine and limaprost alfadex: a case report. Prim Care Companion J Clin Psychiatry 2007;9:240-1.
24. Petersen I, Douglas I, Whitaker H. Self controlled case series methods: an alternative to standard epidemiological study designs. BMJ 2016;354:i4515.
27. Yamamoto T, Hiromoto J. Phase I clinical trial of 17(S)-methylomega-homo-trans-delta2-prostaglandinE1 ∙ α-cyclodextrin (OP-1206 ∙ α-CD): part 2. 5-day repeated dose study. Yakuri To Chiryo 1981;9:1935-45. (Japanese).
29. Maeda Y, Kanayama S, Okajima Y, et al. Effect of PGE1 analogue (ONO-1206) on the platelet functions. Blood Vessel 1982;13:142-5. (Japanese).
30. Tsuboi T, Fujitani B, Maeda J, et al. Effect of OP 1206, a prostaglandin E1 derivative, on guinea-pig platelet functions. Thromb Res 1980;20:573-80.
31. Fujitani B, Watanabe M, Kuwashima J, et al. Effect of a prostaglandin E1 derivative (OP-1206) and acetylsalicylic acid on electrically induced thrombosis in guinea-pig mesenteric artery and its modification by an inhibitor of prostaglandin I2 synthetase, tranylcypromine. Jpn J Pharmacol 1986;40:31-5.